1	Atovaquone for Treatment of COVID-19: A Prospective Randomized, Double-					
2		Blind, Placebo-Controlled Clinical Trial				
3						
4	Mamta K. Jain MD ^{1,3*} , James A. de Lemos MD, ^{2,3} , Darren K. McGuire MD ^{2,3} , Colby					
5	Ayers PhD ² , Jennifer L. Eiston B.S. ⁴ , Claudia L. Sanchez B.S. ¹ , Dena Kamel B.S. ¹ ,					
6	Jessica A. Meisner MD ⁵ , Emilia V. Thomas MD ⁶ , Anita A. Hegde MD ^{3,6} , Satish Mocherla					
7	MD ^{1,3} , Joslyn K. Strebe MD ³ , Xilong Li PhD ⁷ , Noelle S. Williams PhD ⁸ , Chao Xing PhD ⁹ ,					
8	Mahmoud S. Ahmed PhD ² , Ping Wang PhD ² , Hesham A. Sadek MD, PhD ^{1,10*} , and John					
9	W. Schoggins PhD ^{4*}					
10						
11	1	Department of Internal Medicine/Infectious Diseases, University of Texas				
12		Southwestern Medical Center, Dallas, Texas 75390, USA				
13	2	Department of Internal Medicine/Cardiology, University of Texas Southwestern				
14		Medical Center, Dallas, Texas 75390, USA				
15	3	Parkland Health & Hospital System, Dallas, Texas 75235 USA				
16	4	Department of Microbiology, University of Texas Southwestern Medical Center,				
17		Dallas, Texas 75390, USA				
18	5	Department of Internal Medicine/Infectious Diseases, University of Pennsylvania,				
19		Philadelphia, Pennsylvania 19104 USA				
20	6	Department of Internal Medicine/Hospital Medicine, University of Texas				
21		Southwestern Medical Center, Dallas, Texas 75390, USA				
22						

23	7	Department of Population and Data Science, University of Texas Southwestern
24		Medical Center, Dallas, Texas, 75390, USA
25	8	Department of Biochemistry, University of Texas Southwestern Medical Center,
26		Dallas, Texas 75390, USA.
27	9	McDermott Center for Human Growth and Development, University of Texas
28		Southwestern Medical Center, Dallas, Texas 75390, USA.
29	10	Departments Biophysics, and Molecular Biology, and Center for Regenerative
30		Science and Medicine, University of Texas Southwestern Medical Center, Dallas,
31		Texas 75390, USA.
32		
33		
34		
35		
36		
37		
38		
39		
40		
41		
42		
43		
44		
45		

- 46 * Author(s) of correspondence
- 47 **Correspondence to:**
- 48 Mamta K. Jain, MD, MPH
- 49 Professor of Internal Medicine, Division of Infection Diseases and Geographic Medicine,
- 50 UT Southwestern Medical Center
- 51 Mamta.jain@utsouthwestern.edu
- 52 Tel: (214)648-3111
- 53
- 54 Hesham A. Sadek, MD, PhD
- 55 Professor of Internal Medicine/Cardiology, Molecular Biology, and Biophysics, UT
- 56 Southwestern Medical Center
- 57 <u>Hesham.sadek@utsouthwestern.edu</u>
- 58 Tel: (214)648-1413
- 59
- 60 John Schoggins, PhD
- 61 Associate Professor of Microbiology, UT Southwestern Medical Center
- 62 John.schoggins@utsouthwestern.edu
- 63 Tel: (214)648-3111
- 64
- 65 Word Count: 3067
- 66
- 67
- 68

69

70 ABSTRACT

71

Background: An in-silico screen was performed to identify FDA approved drugs that inhibit SARS-CoV-2 main protease (M^{pro}), followed by in vitro viral replication assays, and in vivo pharmacokinetic studies in mice. These studies identified atovaquone as a promising candidate for inhibiting viral replication.

76

Methods: A 2-center, randomized, double-blind, placebo-controlled trial was performed 77 among patients hospitalized with COVID-19 infection. Enrolled patients were 78 79 randomized 2:1 to atovaquone 1500 mg BID versus matched placebo. Patients 80 received standard of care treatment including remdesivir, dexamethasone, or 81 convalescent plasma as deemed necessary by the treating team. Saliva was collected 82 at baseline and twice per day for up to 10 days for RNA extraction for SARS-CoV-2 viral 83 load measurement by quantitative reverse-transcriptase PCR. The primary outcome was the between group difference in log-transformed viral load (copies/mL) using a 84 85 generalized linear mixed-effect models of repeated measures from all samples.

86

Results: Of the 61 patients enrolled; 41 received atovaquone and 19 received placebo.
Overall, the population was predominately male (63%) and Hispanic (70%), with a mean age of 51 years, enrolled a mean of 5 days from symptom onset. The log₁₀ viral load was 5.25 copies/mL vs. 4.79 copies/mL at baseline in the atovaquone vs. placebo group. Change in viral load did not differ over time between the atovaquone plus

standard of care arm versus the placebo plus standard of care arm. Pharmacokinetic
(PK) studies of atovaquone plasma concentration demonstrated a wide variation in
atovaquone levels, with an inverse correlation between BMI and atovaquone levels,
(Rho -0.45, p=0.02). In post hoc analysis, an inverse correlation was observed between
atovaquone levels and viral load (Rho -0.54, p= 0.005).

Conclusion: In this prospective, randomized, placebo-controlled trial, atovaquone did 99 not demonstrate evidence of enhanced SARS-CoV-2 viral clearance compared with 100 placebo. However, based on the observed inverse correlation between atovaquone 101 levels and viral load, additional PK-guided studies may be warranted to examine the 102 antiviral effect of atovaquone in COVID-19 patients.

104 clincialtrials.gov (NCT04456153).

- 4 4 4

115

116 **INTRODUCTION**

117

118 SARS-CoV-2 was identified in late December 2019 as the causative agent of a severe acute respiratory syndrome named COVID-19[1-3]. Targeting the disease in the initial 119 phase with an effective oral agent that can be used in the outpatient setting could 120 121 mitigate the progression to severe disease and decrease need for hospitalization and 122 mortality. As such, a large number of clinical trials have focused on testing a wide range of antiviral drugs against SARS-CoV-2. A clinicaltrials.gov search at the time this 123 manuscript was written (May 2021), there were over 540 ongoing or completed clinical 124 125 trials testing potential antivirals agents against SARS-CoV-2. These antivirals include 126 new and repurposed drugs targeting viral proteins that are critical for viral replication such as the proteases (main protease (Mpro) and papain-like protease) and RNA 127 128 polymerase among others. For example, the first FDA approved antiviral drug against 129 SARS-CoV-2 was remdesivir, which was originally developed for the Ebola virus, and 130 has been successfully repurposed as a SARS-CoV-2 RNA polymerase inhibitor. 131 Recently, Merck pharmaceuticals announced that Molnupiravir, an oral anti-viral agent, 132 decreased the risk of hospitalization from COVID-19 by about 30% [4-6]. Also, Pfizer announced the clinical outcomes for their oral SARS-CoV-2 M^{pro} inhibitor, Paxlovid, that 133 134 reduced risk of hospitalization or death by 89% (within three days of symptom onset) 135 and 88% (within five days of symptom onset) compared to placebo[7, 8]. Both drugs were granted U.S. FDA Emergency Use Authorization. These new drugs however are 136 137 unlikely to be widely available worldwide soon.

138

139 SARS-CoV-2 is an enveloped, single-stranded RNA betacoronavirus, with a genome 140 size of 29,891 bases encoding for 29 proteins. The SARS-CoV-2 genome encodes several nonstructural proteins including main protease (M^{pro} or 3Cl^{pro}), and papain-like 141 protease (PLpro)[9]. Given the critical role that these proteins play in viral entry and 142 143 replication, they have been the topic of intense bench and clinical studies. The first SARS-CoV-2 protein to be crystalized is the M^{pro} protein, which plays a critical role in 144 145 generation of the viral proteome by cleaving viral polyproteins into individual proteins, resulting in generation of 12 non-structural proteins, including RNA-dependent RNA 146 polymerase and helicase, which are required for viral replication. M^{pro} cleaves its target 147 polypeptides after sequences that include the amino acid glutamine, and its substrate 148 binding pocket is structurally unrelated to any human protease, and thus M^{pro} is a viable 149 150 drug target for inhibition of SARS-CoV-2 replication [10-12].

151

152

A recent study performed an in-silico screen[13], followed by cell-based viral assays with authentic SARS-CoV-2 and identified several FDA approved drugs with antiviral activity. One drug, atovaquone, had an IC50 against SARS-CoV-2 that falls within its therapeutic range, although the antiviral effect of atovaquone does not appear to be primarily mediated by its M^{pro} inhibitory activity[13]. Based on the virocidal, pharmacokinetic and side effect profiles, as well as global drug availability, we chose atovaquone as a candidate for clinical testing. Here we report results of a 2-center,

prospective, randomized, placebo-controlled clinical trial examining the antiviral effect of
 atovaquone in hospitalized COVID-19 patients.

162

163 **METHODS**

164 **Design:** This is a randomized, double-blind, placebo-controlled trial of atovaguone therapy in adult participants hospitalized with COVID-19. Enrollment into the trial began 165 166 in July 22, 2020 and was completed on December 29, 2020 with 1 month follow-up 167 completed January 26, 2021. There were two clinical trial sites located in Dallas, Texas 168 Eligible participants were randomized in 2:1 fashion to atovaguone or matching placebo. 169 The treatment group received atovaquone 1500mg BID PO for 10 days or matching 170 placebo bid for up to 10 days, during hospitalization and after discharge. Participants 171 could receive all available standard of care therapy under Emergency Use Authorization 172 including remdesivir, dexamethasone and convalescent plasma as prescribed by the 173 treating team. Atovaguone or placebo was administered orally or by nasogastric tube 174 and was given with a meal or snack when possible. The trial protocol was approved by UT Southwestern Institutional Review Board and was overseen by an independent data 175 176 safety and monitoring board, and all patients provided written informed consent. The 177 trial was funded by a grant from UT Southwestern.

178

Eligibility: Patients were eligible if they had a positive polymerase chain reaction test for SARS-CoV-2 within 72 hours of hospitalization, \geq 18 years of age, able to provide informed consent, and anticipated hospitalization for \geq 48 hours. Patients were excluded if they met any of the following criteria: enrolled in another COVID-19 antiviral therapy,

183 breastfeeding women, known hypersensitivity to atovaquone, treatment with rifampin, 184 patients with AIDS who required treatment for *Pneumocystis jirovecii* or *Toxoplasma* 185 *gondii*, not expected to survive for 72 hours, >14 days from symptom onset. 186 187 Randomized interventions: Atovaguone/placebo: Atovaguone and matching placebo were supplied by Pharmacy Solutions (Arlington, Texas). 188 189 190 Randomization: Randomization blocks of 12 were given separately to each site pharmacist and after a patient signed informed consent and eligibility was verified, a 191 randomization code was given for each participant. 192 193 194 **Procedures:** After randomization, 2 ml of saliva was collected from each participant 195 and mixed with 2 ml of the preservative DNA/RNA Shield (Zymo Research) prior to 196 administration of trial drug, and then repeated every evening and morning while the 197 participant was in the hospital. Saliva, instead of nasopharyngeal swab, was collected 198 because it provides a reliable viral load measurement, [14] and minimizes patient

involved in the design, analysis, and writing of the manuscript. Other investigators contributed in collection of data. All investigators reviewed the manuscript. The trial is registered on clincialtrials.gov (NCT04456153).

discomfort. Plasma and serum were collected at baseline (Day 1) and Day 3 and 5 of

follow-up if still hospitalized. A telephone follow-up occurred at 2 and 4 weeks after

randomization if the patient was discharged. All investigators remained blinded to study

assignment until completion of follow-up and database lock. The lead investigators were

199

200

201

202

206

207 <u>**RNA Isolation:**</u> Saliva was collected using the DNA/RNA Shield Saliva Collection Kit 208 (Zymo Research) following the manufacturer's protocol. 1-2 ml of saliva/Shield mix was 209 incubated with DTT (Life Technologies) following the U.S. Department of Health and 210 Human protocol (https://www.cdc.gov/coronavirus/2019-ncov/downloads/processing-211 sputum-specimens.pdf). The samples were then treated with Proteinase K (Zymo 212 Research) following the manufacturer's protocol. RNA was extracted using the Direct-213 zol RNA Miniprep Kit (Zymo Research).

214

215 SARS-CoV-2 positive control: SARS-CoV-2 N gene was amplified from a synthesized 216 N gene fragment (IDT) with primers that introduced a T7 promoter sequence on the 3' 217 end (IDT). The PCR product was purified using Qiagen PCR Purificaton Kit (Qiagen). In 218 vitro transcription was performed using T7 RiboMAX Express Large Scale RNA Production System following the manufacturer's protocol (Promega). RNA was 219 220 quantitated by spectrophotometry on a DS-11 FX instrument (Denovix) and by 221 fluorometer assay using the DeNovix RNA Assay. In vitro transcribed RNA was used to generate a standard curve for qPCR from a 10-fold dilution series starting at 5 x 10¹⁰ 222 223 copies of RNA.

224

<u>RT-qPCR:</u> RT-qPCR was performed in a 20 µl reaction containing 5 or 10 µl RNA, 5 µl
TaqMan Fast Virus 1-Step Master Mix, 600 nM each primer, and 150 nM probe. 10 µl
RNA was used for the detection of SARS-CoV-2 and 5 µl RNA for detection of GAPDH.
SARS-CoV-2 primers and probe were designed as recommended by the Center for

Disease Control (https://www.cdc.gov/coronavirus/2019-ncov/lab/rt-pcr-panel-primerprobes.html). GAPDH primers and probe were designed as previously reported[10]. All oligonucleotides were synthesized by LGC Biosearch Technologies. RT was performed at 50°C for 5 minutes, followed by inactivation at 95°C for 2 minutes, and 40 cycles of PCR (95°C for 3 seconds, 60°C for 30 seconds) on an ABI 7500 Fast thermocycler or a QuantStudio 3 (Applied Biosystems).

235

Analysis of RT-gPCR data. For each 96-well plate, a standard curve of N gene 236 237 dilutions was run as described above. A simple linear regression model was used to fit 238 the Ct values from the standard curve and subsequently interpolate RNA concentrations from saliva samples. Across all 96-well plates, the R² value for goodness of fit was 0.97 239 240 or higher. The lower limit of detection of the assay was 50ng N gene control RNA. 241 GAPDH Ct values were obtained for all samples. Samples that had undetectable 242 GADPH levels, a total of 7, were removed from the analysis. The GAPDH Ct values of 243 the remaining samples were analyzed using the ROUT method for outlier analysis with a 1% threshold. This resulted in additional 4 samples being removed from the data set. 244 The final data set contained 614 samples. SARS-CoV-2 RNA copies/mL were 245 246 interpolated from the standard curves, and log-transformed data were analyzed.

247

248 <u>Outcomes and Statistical Analysis:</u> Any sample with no detectable GADPH 249 housekeeping and any with GADPH Ct >34 was prospectively omitted. Values below 250 detection limit were assigned a value ½ between lowest detection limit and zero. All 251 analyses were intention-to-treat.

252

253 The primary outcome was log transformed viral load (copies/mL) using generalized 254 linear mixed-effect models of repeated measures (GLMM) using data from all samples 255 and timepoints. Random intercepts with an unstructured covariance structure was used 256 in the models. Time point differences were statistically assessed through contrast tests 257 with the appropriate combination of the fixed effects of treatment group, time, and 258 treatment group by time interactions. No adjustment was made for multiple 259 comparisons. Statistical significance was set using alpha=0.05, and all analyses were 260 performed using SAS version 9.4.

261

262 Secondary outcomes were (1) viral load (log copies/mL) at 2 days, 4 days, and 7 days after randomization. (2) Area under the curve (AUC) of viral load (log copies/mL) 263 264 through day 3 and 7 using the trapezoidal rule. (3) Between group differences in viral load (log copies/mL) using GLMM stratified by morning and evening samples, use of 265 266 remdesivir, median split of baseline values (high vs. low viral load), median split time from onset of symptoms (<5 days vs. \geq 5 days, median split of body mass index (BMI), 267 268 diabetes status, sex and age. (4) Time to 2 log unit decrease in viral load using 269 Kaplan-Meier estimates.

Subgroup analyses evaluated the primary endpoint stratified by morning and evening samples, use of remdesivir, sex, diabetes status and median baseline viral load (high vs. low viral load), time from onset of symptoms (<5 days vs. \geq 5 days), body mass index (BMI), and age. Our exploratory clinical outcome was to examine \geq 2 point change in

ordinal scale (where higher scores are associated with clinical improvement) at Day 5
by chi-square analysis as described previously[15].

276

Pharmacokinetic Analysis: Blood was drawn from participants prior to drug being given on Day 1 (which is baseline). Patients received drug at approximately 5 pm on day 1 then twice per day thereafter (approximately 9 am and 5 pm). Blood was drawn on Day 3 in the morning and Day 5 in the morning (if patient was still in hospital) between 5 and 8 am.

282

283 Analysis of patient specimens utilized standard blood-borne pathogen precautions. Day 284 1 pre-dose samples were pooled and evaluated as blanks. Analysis was blinded to 285 patient group, so samples from patients receiving placebo were analyzed in the same 286 fashion as samples from patients receiving drug. Day 3 and 5 samples were diluted 1:25 or 1:50 in a total volume of 50 µL of commercial human plasma (BioIVT 287 288 HMPLEDTA2, Lot BRH465874). To all samples, 10µL of internal standard 289 (atovaquone-d4) diluted in 30 mM NH₄ Acetate was added and samples vortexed. 400 290 µL of ethyl acetate was added to each sample. Tubes were vortexed for 30 sec, 291 incubated at room temperature (RT) for 5 minutes and spun for 5 minutes at 16,100 x g. 292 Supernatant was transferred to a second tube. To the first tube, 400 µL of ethyl acetate 293 was added. Tubes were vortexed for 15 sec, incubated at RT for 5 minutes and spun 294 for 5 minutes at 16,100 x g. Supernatant was removed and added to tube containing 295 supernatant previously collected. Samples were dried down under vacuum and then 296 resuspended in 100 µL of 20:80 dH₂O:ACN, 5mM NH₄ Acetate. Samples were

297 vortexed for 15 seconds, sonicated for 3 minutes and spun for 5 minutes at 16,100 x g. 298 Supernatant was transferred to an HPLC vial and analyzed on a Sciex 4000QTRAP 299 coupled to a Shimadzu Prominence LC using a fit-for-purpose method. Atovaguone 300 was detected in negative multiple reaction monitoring (MRM) mode using the following 365.096 to 337.0 (quantitation ion), 365.096 to 170.8 (qualifier ion). 301 transitions: 302 Atovaquone-d4 was detected using the 369.1 to 341.0 transition. An isocratic flow of 0.2 303 mL/min 2 mM NH₄ acetate with 0.8 mL/min of acetonitrile on an Agilent C18 XDB 304 column (5-micron, 50 x 4.6 mm) was used for chromatography. Atovaguone and 305 Atovaguone-d4 showed a retention time of 1.73 min using this method. Concentrations 306 were determined by comparison to a 9-point standard curve prepared by spiking blank 307 human plasma with atovaquone standards made in DMSO. Standards and quality 308 control (QC) samples were run twice with 14/18 standards and 7/8 QC's showing back-309 calculated values with 15% of nominal. The limit of detection (LOD) was defined to be 310 three-fold above the signal observed in blank plasma and the limit of quantitation (LOQ) 311 was defined as the lowest point on the standard curve above the limit of detection and 312 within 20% of nominal. The LOQ was 5 ng/mL. Recovery of analyte at low, medium and 313 high concentrations was >93%. Final atovaquone levels were calculated as µg/ml at 314 days 3 and day 5 following initiation of atovaguone therapy.

315

316 **RESULTS**

Of the 61 patients who signed consents, 60 underwent 2:1 randomization; 41 were assigned to atovaquone group and 19 to the placebo group. Overall the population was predominately male and Hispanic with a mean age of 51 years. The two groups were

balanced (Table 1) with regard to age, sex, race, co-morbidities, days from onset of
 symptoms, baseline oxygen requirements, and receipt of COVID-19 specific standard of
 care treatment. A higher proportion of participants with diabetes were in the atovaquone
 arm.

324

325 Primary Outcome

The log₁₀ viral load was 5.25 copies/mL vs. 4.79 copies/mL at baseline in the atovaquone vs. placebo group and decreased in both groups over time. No differences in viral load over time were seen between the atovaquone plus standard of care arm versus the standard of care arm (**Figure 1A and 1B**).

330

331 Secondary Outcomes

332 Two days after intervention, the viral load was 5.37 copies/mL vs. 4.43 copies/mL in the atovaquone vs. placebo arm. Four days after intervention, the viral load was 4.22 333 334 copies/mL vs. 3.76 copies/mL and 7 days after the intervention, the viral load was 3.92 335 copies/mL vs. 3.71 copies/mL in atovaquone vs. placebo group. No differences were seen between the groups in any of the days. The AUC for viral load was 36.09 vs. 336 337 38.39, p=0.76 in the atovaguone compared with the placebo arm. There were no 338 differences between groups in viral load over time in subgroup analyses stratified by 339 sex, age, diabetes, time of sample collection, use of remdesivir, symptom onset of ≥ 5 340 days vs. <5 days, high versus low viral load. At Day 5, >2 point change in ordinal score 341 occurred in 8 of 41 in atovaquone and 1 of 19 in placebo, p=0.30. At Day 15, >2 point

change in ordinal scale occurred in 25 of 40 in atovaquone and 9 of 17 in placebo,p=0.68.

344

345 <u>Atovaquone levels</u>

Day 3 drug levels (7.668 μ g/mL) were significantly lower than those on day 5 (11.590 μ g/mL) (p =<0.01) (**Figure 2**), suggesting that steady state plasma concentration was not reached by 3 days. Analysis of the correlation between BMI and drug levels revealed a statistically significant inverse correlation between BMI and atovaquone levels, (Spearman rho -0.45, p= 0.02) (**Figure 3**). Interestingly, there was an inverse correlation between atovaquone levels and viral load (rho -0.54, p =0.005) (**Figure 4**).

352

353 <u>Safety</u>

There were 45 grade 3 or higher adverse events; 30 in the atovaquone arm and 15 in the placebo arm. There were two grade 3 adverse events thought to be related to study drug one in the atovaquone arm and one in the placebo arm. Non-serious adverse events thought to possibly related to study drug included hyponatremia, transaminitis, nausea/vomiting, and diarrhea. Overall, there was a total of 8 (13.3%) deaths in the trial, with 6 (14.6%) vs. 2 (10.5%), p=0.44 in the atovaquone vs. placebo group 28 days after intervention.

361

362

363 **DISCUSSION**

In this prospective, randomized, placebo-controlled clinical trial of 60 patients, no effect on viral clearance was observed in patients treated with atovaquone compared with placebo. This trial was not powered to examine clinical efficacy. The results of present trial also demonstrated that atovaquone in patients hospitalized with COVID-19 was well tolerated. There was no significant difference in either severe adverse events or death in the atovaquone treated group.

371

372 The secondary outcomes and post-hoc analyses highlight several factors that may help 373 explain why atovaquone did not show a significant effect on viral load compared with 374 placebo as pre-specified in the primary outcome. First, the preclinical study that 375 identified atovaquone did not test its antiviral effect in vivo in an animal model, and thus 376 the *in vitro* antiviral effect in cell culture might not be directly translatable clinically. 377 Second, atovaquone was administered in a hospitalized patient population, in which 378 almost two-thirds received remdesivir as part of standard of care therapy, and thus it is 379 possible that an antiviral effect of atovaquone was overshadowed by remdesivir. 380 Importantly, although one-third of participants did not receive remdesivir, this study size 381 was too small to allow exploration of the antiviral effects of atovaquone in patients not 382 receiving remdesivir. It is also possible that measuring viral load in upper respiratory 383 samples may not be a sensitive indicator for viral replication.

384

Another possibility for not detecting significant changes in viral kinetics in the overall population may be the inability to achieve inhibitory free drug concentration levels in some patients. Atovaquone has a long half-life and is highly plasma protein bound. The

388 present study assessed the highest approved dose of 1500 mg twice daily. Based on 389 PK/PD data from studies of Pneumocystis jirovecii[16, 17], and PK studies in 390 rodents[13], it was postulated that IC50-equivalent therapeutic plasma levels could be 391 achieved. Our in vitro data indicated that the free atovaquone IC50 for SARS-CoV-2 392 antiviral activity in Vero cells is 1.2 nM based on a total IC50 of 1.5 µM and unbound 393 fraction (f_{u}) for atovaquone of 0.0008 in tissue culture media (N. Williams, unpublished). 394 According to DrugBank, atovaguone is reported to be highly protein bound in plasma 395 (>99.9%). Our preliminary analysis of atovaquone binding to human plasma supports this observation ($f_{\mu} = 0.00003$), suggesting that total drug levels of at least 40 μ M (15 396 µg/mL) are needed. This, of course, assumes that the IC50 calculated in Vero cells is 397 398 relevant for COVID-19 disease in vivo.

399

However, the PK data using samples collected from patients in the present trial indicate that IC50-equivalent drug levels were not achieved in most patients at 3 days after initiation of atovaquone, and only a subset of patients achieved adequate levels at day 5. Given that the trial was restricted to patients hospitalized with COVID-19, an antiviral effect during the early phase of the disease, when antivirals are most likely to have a therapeutic effect, was not tested in the current trial.

406

Importantly, the results highlight the potential role BMI may play with regard to atovaquone plasma concentrations. The present PK studies revealed two important findings: first, the inverse correlation between atovaquone plasma concentration and BMI is a strong indicator that patients with higher BMI may need higher dosing. Second,

an inverse correlation was observed between atovaquone levels and viral load, which
could suggest an antiviral effect of atovaquone on SARS-CoV-2 if adequate drug levels
are achieved. However, the post-hoc nature of these findings preclude making reliable
conclusions, and thus further PK-guided studies may be needed to determine the role of
atovaquone in treatment of COVID-19 patients.

- 416
- 417

418 Acknowledgements

This trial was supported by funds from the Mary Kay Family Foundation and the Office 419 of the President, UT Southwestern Medical Center. We are grateful for the following 420 members of the Data Safety and Monitoring Board who reviewed the interim analysis: 421 422 William M. Lee, MD; Kelly Chin, MD; Justin Grodin, MD; Joan Reish, PhD. We are 423 grateful for Ezimamaka Ajufo, MD and Lorrie Burkhalter for developing data dictionary and RedCap instrument. The clinical team and pharmacy teams who assisted include: 424 425 Tianna Petersen, MS; Laura Hansen, MS; Minerva Santos, Azadeh Mozaffari, Pharm D; Christine Cha, PharmD; Natalie Dellavalle; PharmD; Sonia Gonzales, PharmD. 426 Pharmacokinetic analyses were conducted by the Preclinical Pharmacology Core at UT 427 428 Southwestern Medical Center. HAS was funded by Center for Regenerative Science and Medicine at UT Southwestern Medical Center. 429

- 430
- 431

432 Conflict of interest

433	MKJ has received research funding from Gilead Sciences and Regeneron and was on
434	Advisory Board for Gilead Sciences. SM received research funding from Regeneron.
435	JAdL has received consulting income from Regeneron and Eli Lilly unrelated to COVID-
436	19. JWS serves as a consultant for the Federal Trade Commission on matters related to
437	COVID-19 treatments.
438	
439	
440	
441	
442	
443	
444	
445	
446	
447	
448	
449	
450	
451	
452	
453	
454	
455	

456 TABLE 1: Demographics and Clinical Characteristics at Baseline

	Overall	Atovaquone	Placebo	P value
	N(%)	(n=41)	(n=19)	
		N (%)	N(%)	
Gender				
Male	38 (63)	26 (63)	12 (63)	1.0
Race				
White	46 (77)	31 (76)	15 (79)	1.0
Black	8 (13)	6 (15)	2 (11)	
Ethnicity				
Hispanic	42 (70)	29 (71)	13 (68)	1.0
Age, mean yeas (IQR)	50.9 (41.9,	51.64 (42.5,	49.4 (41, 59.6)	0.56
	59.6)	60.8)		
BMI, mean	32.78	32.65(27.1,	33.07 (26.8,	0.86
	(27,36.5)	35.9)	37.1)	
Co-morbidities				
Hypertension	38 (63)	26 (63)	12 (63)	1.0
Diabetes	38 (63)	30 (73)	8 (42)	0.04
Obesity	23 (38)	15 (37)	8 (42)	0.78
Chronic kidney disease	20 (33)	12 (29)	8 (42)	0.38
Lung disease [#]	12 (20)	10 (24)	2(11)	0.31
Heart disease [^]	7(12)	5 (12)	2 (11)	1.0
Cancer	6 (10)	3 (7)	3 (16)	0.37

transplant	5 (8)	2 (5)	3 (16)	0.31
liver disease	5 (8)	4 (10)	1 (5)	1.0
Vascular	4 (7)	2 (5)	2 (11)	0.23
Other	3 (5)	1 (2)	2 (11)	0.26
Other treatment				
On remdesivir		27 (66)	9 (47)	0.26
On dexamethasone		30 (73)	14 (74)	1
Plasma		4 (10)	1 (5)	1
Other characteristics				
Days from symptom	5.15 (4,6)	5.24 (4,7)	4.95 (4,6)	0.56
onset, mean days				
(IQR)				
Oxygen status at				0.57
baseline				
Room air	17 (28.3)	10 (24.4)	7 (36.8)	
Low flow oxygen	40 (66.7)	29 (70.7)	11 (57.9)	
High flow oxygen	3 (5)	2 (4.9)	1 (5.3)	

457

458 [#] Chronic obstructive pulmonary disease, asthma, smoking

459 [^] Congestive heart failure, myocardial infarction, coronary artery disease,
460 cardiomyopathy

461 * Autoimmune, connective tissue, peptic ulcer, HIV

462 Figure Legends:

Figure 1. Primary Outcome. A) Mean log SARS-CoV-2 viral RNA in placebo compared to atovaquone over the 10-day trial period. **B)** Viral load decline in placebo and atovaquone groups. No statistically significant difference was detected between the two groups.

467

Figure 2. Atovaquone Plasma Concentration. Atovaquone plasma concentration
measured at day 3 and 5 following initiation of therapy. Day 3 drug levels were
significantly lower than those of day 5. (** p<0.005).

471

Figure 3. Correlation Between Atovaquone Plasma Concentration and BMI.
Pharmacokinetic studies showed a negative correlation between atovaquone and BMI 5
days following initiation of atovaquone (rho -0.45, p-0.02).

475

476 **Figure 4. Correlation Between Atovaquone Plasma Concentration and Viral Load.**

477 Mean log SARS-CoV-2 viral RNA showed an inverse correlation with atovaquone 478 plasma concentration (rho -0.54, p-0.005).

479

480

- 481
- 482
- 483

485 **Figure 1: Primary Outcome**









577 **REFERENCES**

578

- 580 1. Malik YS, Sircar S, Bhat S, et al. Emerging novel coronavirus (2019-nCoV)-current scenario,
 581 evolutionary perspective based on genome analysis and recent developments. Vet Q 2020;
 582 40:68-76.
- 583 2. Wu F, Zhao S, Yu B, et al. A new coronavirus associated with human respiratory disease in 584 China. Nature **2020**; 579:265-9.
- 585 3. Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of 586 probable bat origin. Nature **2020**; 579:270-3.
- 587 4. Rosenke K, Hansen F, Schwarz B, et al. Orally delivered MK-4482 inhibits SARS-CoV-2 588 replication in the Syrian hamster model. Nature Communications **2021**; 12:2295.
- 589 5. Cox RM, Wolf JD, Plemper RK. Therapeutically administered ribonucleoside analogue MK-590 4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets. Nature Microbiology **2021**; 6:11-8.
- 591 6. Fischer W, Eron JJ, Holman W, et al. Molnupiravir, an Oral Antiviral Treatment for COVID-19.
- 592 medRxiv : the preprint server for health sciences **2021**:2021.06.17.21258639.
- 593 7. Owen Dafydd R, Allerton Charlotte MN, Anderson Annaliesa S, et al. An oral SARS-CoV-2 594 Mpro inhibitor clinical candidate for the treatment of COVID-19. Science **2021**; 374:1586-93.
- 595 8. Mahase E. Covid-19: Pfizer's paxlovid is 89% effective in patients at risk of serious illness, 596 company reports. Bmj **2021**; 375:n2713.
- 597 9. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 598 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell **2020**.
- 10. Mengist HM, Dilnessa T, Jin T. Structural Basis of Potential Inhibitors Targeting SARS-CoV-2
 Main Protease. Front Chem **2021**; 9:622898.
- 601 11. Mohammad T, Shamsi A, Anwar S, et al. Identification of high-affinity inhibitors of SARS-
- 602 CoV-2 main protease: Towards the development of effective COVID-19 therapy. Virus Res **2020**; 603 288:198102.
- for a second seco
- Mahmoud Ahmed AF, Ping Wang , Ian N. Boys , Jennifer L. Eitson , Maikke B. Ohlson
 ,Wenchun Fan , Matthew B. McDougal , John W. Schoggins , Hesham Sadek. Identification of
 Atovaquone as and Mebendazole as Repurposed Drugs with Antiviral Activity against SARS-CoV-
- 6092chemRxiv2021;https://chemrxiv.org/engage/chemrxiv/article-610details/612ff2f8abeb6328b6c624cd.
- 611 14. Wyllie AL, Fournier J, Casanovas-Massana A, et al. Saliva or Nasopharyngeal Swab
 612 Specimens for Detection of SARS-CoV-2. N Engl J Med 2020; 383:1283-6.
- 613 15. Davey RT, Jr., Fernandez-Cruz E, Markowitz N, et al. Anti-influenza hyperimmune
- 614 intravenous immunoglobulin for adults with influenza A or B infection (FLU-IVIG): a double-
- 615 blind, randomised, placebo-controlled trial. Lancet Respir Med **2019**; 7:951-63.

- 616 16. Robin C, Le MP, Melica G, et al. Plasma concentrations of atovaquone given to
- 617 immunocompromised patients to prevent Pneumocystis jirovecii. J Antimicrob Chemother 618 **2017**; 72:2602-6.
- 619 17. Calderon MM, Penzak SR, Pau AK, et al. Efavirenz but Not Atazanavir/Ritonavir Significantly
- 620 Reduces Atovaquone Concentrations in HIV-Infected Subjects. Clin Infect Dis **2016**; 62:1036-42.